Board & Management
Sten R. Sörensen, b. 1959. Chairman of the Board
Degree in biochemistry from Lund University, Sweden. Has extensive experience in the pharmaceutical, biotech, finance and board work. Sörensen has held several senior global marketing positions within AstraZeneca and Monsanto, and has worked with several start-up companies. CEO of Cereno Scientific AB (listed on AktieTorget 2016) and Chairman of SARomics Biostructures AB.
Holdings in AcuCort: 4 000 shares through Bridge Consulting and option rights to buy 40 000 shares in 2020.
Bengt-Åke Bengtsson, b. 1944. Director of the Board.
Prof. of Clinical Endocrinology at the University of Gothenburg, Sweden. One of the co-founders of the pharmaceutical company Tercica, listed on the US Nasdaq and sold to the French pharmaceutical company Ipsen. Bengtsson has held Director of the Board assignments of several companies and is currently Chairman of the renal oncology company Oncorena. Since many years, he is a partner of P.U.L.S. AB.
Holdings in AcuCort: 93.600 shares.
Lennart Bruce, b. 1944. Director of the Board.
PhD in animal physiology, Lund University, Sweden. Lennart has 40 years in the pharmaceutical industry and has extensive experience in drug development. Bruce was one of the founders of Biovitrum and has started, and is now managing, Viken Pharma AB and Viken Pharma Consulting. Broad board experience from a number of biotech companies in several countries. Partner in P.U.L.S. AB.
Holdings in AcuCort: 73.000 shares and an additional 15.000 shares through Viken Pharma.
Anna Eriksrud, b. 1958. Director of the Board.
International MBA from Uppsala University, Sweden. Eriksrud has a background as a health care entrepreneur with over 25 years of experience in the medical and pharmaceutical sector, primarily from Q-Med and Pharmacia. She has run her own business through Apoteksamariten and has leadership experience from international cross-functional teams, establishing new market categories and launching global brands both in Europe and the US.
Holdings in AcuCort: 6.500 shares.
Sarah Fredriksson, b. 1968. Director of the Board.
M.Sc. in Biotechnology from the Faculty of Engineering (LTH, Lunds Tekniska Högskola) and a PhD from Applied Biochemistry, Lund University, Sweden. Currently CEO of P.U.L.S. AB. Founder and former CEO of Genovis AB, listed at Firth North, Nasdaq OMX Nordic, and with subsidiaries in the US and Sweden. Fredriksson has broad experience of strategic business development on a global market, financing of development companies as well as marketing and sales of new life science products. Fredriksson has currently several board of director’s assignments at a number of life science companies and of Sparbanksstiftelsen Skåne’s Riskkapitalstiftelse.
Holdings in AcuCort: No shares.
Göran Kvist, b. 1950. Director of the Board.
Pharmacist, focusing in biochemistry, Uppsala University, Sweden. Long experience of good manufacturing practice (GMP). Has served on the board of several companies, including CEO and Chairman of the TQ Quality AB and chairman and founder of QP Support AB. Kvist held several QA and QC management positions within the Pharmacia Group, with global development projects and registered pharmaceuticals. Partner in P.U.L.S. AB.
Holdings in AcuCort: 45.000 shares through TQ Kvalitetskonsult.
Mats Lindfors, b. 1957. CEO
International MBA from Lund University, Sweden. 20 years in the life science industry with robust experience from senior positions in sales and marketing and broad experience from the pharmaceutical industry for example Pharmacia among others. Most recent he held a position as Vice President Global Marketing at HemoCue AB, a leading global diagnostic company.
Holdings in AcuCort: 13 000 shares and option rights to buy 120.000 shares in 2020.